Summit Trail Advisors LLC acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,401 shares of the company's stock, valued at approximately $1,893,000.
Several other large investors also recently made changes to their positions in KRYS. Price T Rowe Associates Inc. MD raised its holdings in shares of Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company's stock valued at $117,189,000 after buying an additional 231,255 shares during the period. Segall Bryant & Hamill LLC raised its stake in shares of Krystal Biotech by 352.4% during the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company's stock valued at $28,605,000 after purchasing an additional 122,407 shares during the period. Principal Financial Group Inc. lifted its position in shares of Krystal Biotech by 1,972.0% during the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company's stock worth $22,674,000 after purchasing an additional 117,510 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company's stock valued at $35,583,000 after purchasing an additional 103,928 shares during the period. Finally, Public Sector Pension Investment Board purchased a new position in shares of Krystal Biotech in the second quarter valued at $10,037,000. Institutional investors and hedge funds own 86.29% of the company's stock.
Krystal Biotech Stock Performance
Shares of NASDAQ KRYS traded up $4.16 during trading on Monday, reaching $194.56. The stock had a trading volume of 336,297 shares, compared to its average volume of 326,589. The stock has a market cap of $5.60 billion, a PE ratio of 109.92 and a beta of 0.82. Krystal Biotech, Inc. has a one year low of $99.00 and a one year high of $219.34. The firm's 50 day moving average price is $179.55 and its two-hundred day moving average price is $182.80.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same quarter in the previous year, the firm earned ($0.67) earnings per share. The firm's revenue for the quarter was up 879.9% compared to the same quarter last year. On average, research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have commented on KRYS. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research note on Wednesday, September 11th. HC Wainwright restated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. Citigroup upped their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Finally, Chardan Capital increased their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Krystal Biotech has a consensus rating of "Buy" and an average price target of $202.29.
View Our Latest Stock Report on KRYS
Insider Activity at Krystal Biotech
In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 14.10% of the company's stock.
Krystal Biotech Profile
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
See Also
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
